Spartalizumab

N/A

Report date: 2026/03/17 20:00:15

Base Information

Drug NameSpartalizumab
Drug Alias NamePDR-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUveal melanomaEsophageal adenocarcinomaMetastatic breast cancer +[64] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesFrance National Cancer InstituteNovartis Pharma AgColumbia University +[6] 
Inactive CompaniesDana-Farber Cancer InstituteYonsei UniversityThe University Of Texas MD Anderson Cancer Center
Active IndicationsUveal melanomaEsophageal adenocarcinomaSolid tumours +[44] 
Inactive IndicationsMetastatic breast cancerSkin MelanomaPrimary Myelofibrosis +[20] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG